Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +972-77-2005042 from 8 AM - 11 PM IL

      • Contact
      • Contact

        +972-77-2005042
        from 8 AM - 11 PM IL

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Request More Information
      • Journalists
      • GDPR

      InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

      InMode Logo (PRNewsfoto/InMode)

      News provided by

      InMode Ltd.

      06 May, 2025, 15:03 IDT

      Share this article

      Share this article


      IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of California granted InMode's motion for default judgment against the DHGate sellers and awarded InMode a permanent injunction and damages for the defendants' sales and promotion of counterfeit goods.

      The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includes freezing the assets and halting the listings of the sellers involved in the counterfeit trade. The ruling favors InMode on all claims (trademark infringement, false designation of origin, and California unfair competition), and (1) granted a permanent injunction enjoining the sellers from infringing upon the MORPHEUS® and INMODE® trademarks, and (2) awarded InMode damages per defendant.

      "InMode maintains a zero-tolerance policy towards fraudulent business practices including counterfeit goods and for any platforms or sellers who are using, selling, or distributing false products," says Moshe Mizrahy, CEO of InMode. "We are committed to public safety and will continue to protect consumers from potential harm caused by unauthorized Morpheus8 devices."

      InMode has established a Verified Provider Program for Morpheus8, allowing certified clinics to showcase their authenticity and confirm they use genuine Morpheus8 technology. This initiative helps patients identify safe, authorized providers committed to delivering trusted InMode results.

      Patients in the United States of America and Canada seeking top-quality care from an authorized InMode provider using a trademarked Morpheus8 device can visit the Find a Provider tool at www.inmodemd.com.

      About InMode 

      InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

      Press Contact:
      Behrman Cesa Communications
      [email protected]

      Investor Contact:
      MS-IR LLC
      Miri Segal – Scharia
      [email protected]
      Tel: 917-607-8654

      Logo - https://mma.prnewswire.com/media/1064477/5298285/InMode_Logo.jpg

      SOURCE InMode Ltd.

      Modal title

      Also from this source

      InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

      InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

      InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...

      InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

      InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

      InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution...

      More Releases From This Source

      Contact PR Newswire

      • +972-77-2005042
        from 8 AM - 11 PM IL

      Global Sites

      • APAC
      • APAC - Traditional Chinese
      • Asia
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany

       

      • India
      • Indonesia
      • Israel
      • Italy
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland

       

      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921
      Global Sites
      • Asia
      • Brazil
      • Canada
      • Csezh
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Israel
      • Italie
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      +972-77-2005042
      from 8 AM - 11 PM IL
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • Cookie Settings
      Copyright © 2026 Cision US Inc.